![Long-term prognostic value of longitudinal measurements of blood neurofilament levels | Neurology Neuroimmunology & Neuroinflammation Long-term prognostic value of longitudinal measurements of blood neurofilament levels | Neurology Neuroimmunology & Neuroinflammation](https://nn.neurology.org/content/nnn/7/5/e856/T5/graphic-9.medium.gif)
Long-term prognostic value of longitudinal measurements of blood neurofilament levels | Neurology Neuroimmunology & Neuroinflammation
![PDF) NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab versus fingolimod efficacy in multiple sclerosis PDF) NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab versus fingolimod efficacy in multiple sclerosis](https://www.researchgate.net/publication/328533988/figure/fig2/AS:685984891035652@1540562951657/NEDA-3-Left-panel-Percentage-of-patients-treated-with-natalizumab-black-bars-or_Q320.jpg)
PDF) NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab versus fingolimod efficacy in multiple sclerosis
![(PDF) Molecular anatomy and functions of the choroidal blood-cerebrospinal fluid barrier in health and disease (PDF) Molecular anatomy and functions of the choroidal blood-cerebrospinal fluid barrier in health and disease](https://i1.rgstatic.net/publication/322689889_Molecular_anatomy_and_functions_of_the_choroidal_blood-cerebrospinal_fluid_barrier_in_health_and_disease/links/5fb7ce1092851c933f433734/largepreview.png)
(PDF) Molecular anatomy and functions of the choroidal blood-cerebrospinal fluid barrier in health and disease
![Efficacy and safety of ocrelizumab in patients with relapsing‐remitting multiple sclerosis with suboptimal response to prior disease‐modifying therapies: A primary analysis from the phase 3b CASTING single‐arm, open‐label trial - Vermersch - - European ... Efficacy and safety of ocrelizumab in patients with relapsing‐remitting multiple sclerosis with suboptimal response to prior disease‐modifying therapies: A primary analysis from the phase 3b CASTING single‐arm, open‐label trial - Vermersch - - European ...](https://onlinelibrary.wiley.com/cms/asset/84188f30-c534-4f49-a5a8-6769a35bc872/ene15171-fig-0002-m.jpg)
Efficacy and safety of ocrelizumab in patients with relapsing‐remitting multiple sclerosis with suboptimal response to prior disease‐modifying therapies: A primary analysis from the phase 3b CASTING single‐arm, open‐label trial - Vermersch - - European ...
![Efficacy and safety of ocrelizumab in patients with relapsing‐remitting multiple sclerosis with suboptimal response to prior disease‐modifying therapies: A primary analysis from the phase 3b CASTING single‐arm, open‐label trial - Vermersch - - Efficacy and safety of ocrelizumab in patients with relapsing‐remitting multiple sclerosis with suboptimal response to prior disease‐modifying therapies: A primary analysis from the phase 3b CASTING single‐arm, open‐label trial - Vermersch - -](https://onlinelibrary.wiley.com/cms/asset/32a502b6-33d2-4f45-9339-9a3fb00ab238/ene15171-fig-0003-m.jpg)
Efficacy and safety of ocrelizumab in patients with relapsing‐remitting multiple sclerosis with suboptimal response to prior disease‐modifying therapies: A primary analysis from the phase 3b CASTING single‐arm, open‐label trial - Vermersch - -
![PDF) Human CD4+ T cell subsets differ in their abilities to cross endothelial and epithelial brain barriers in vitro PDF) Human CD4+ T cell subsets differ in their abilities to cross endothelial and epithelial brain barriers in vitro](https://i1.rgstatic.net/publication/338992661_Human_CD4_T_cell_subsets_differ_in_their_abilities_to_cross_endothelial_and_epithelial_brain_barriers_in_vitro/links/5e381017299bf1cdb908bead/largepreview.png)